Article
Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection.
Journal of gastroenterology and hepatology - 1 Dec 2015
Ogawa Eiichi, Furusyo Norihiro, Kajiwara Eiji, Nomura Hideyuki, Kawano Akira, Takahashi Kazuhiro, Dohmen Kazufumi, Satoh Takeaki, Azuma Koichi, Nakamuta Makoto, Koyanagi Toshimasa, Kotoh Kazuhiro, Shimoda Shinji, Hayashi Jun
Abstract excerpt
BACKGROUND AND AIM: The addition of hepatitis C virus (HCV) NS3/4A protease inhibitors to pegylated-interferon alpha (PEG-IFNα) and ribavirin (triple therapy) has greatly improved treatment outcome. The aim of this study was to compare the effectiveness and safety of simeprevir-based or telaprevir-based triple therapy for non-cirrhotic patients in real-world clinical practice. METHODS: This multicenter study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.